Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-01-08 (hitnews.co.kr)
“Aβ alone is not enough, a ‘new’ plan for Alzheimer’s disease treatment is needed” < Planning < Text of article -
[Reporter Shim Ye-seul's BioInsight] We will explore bio-related topics in more depth and introduce various opinions of experts or explain scientific content in detail. The controversy over the anti-amyloid hypothesis, which began in earnest in the mid-2000s, is still ongoing. . Anti-Aβ antibody-based treatments have received attention with FDA approval in the 2020s, but questions about their clinical significance and practical efficacy in treating actual patients are still unresolved. AD research has long been focused on the study of amyloid-beta (Aβ). Accumulation of phosphorylated tau (pTau) protein causes pathology and neurodegeneration
Read more
2024-11-27 (lejdd.fr)
Alzheimer's: the new drug Leqembi, between hope and controversy
After opposing it, the European Medicines Agency has just authorized a new drug against Alzheimer's disease. With the many questions that accompany it.
Read more
2024-11-06 (pharmaphorum.com)
Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal casts long shadow
Cassava Sciences is nearing a Phase 3 readout for its Alzheimer's drug, lecanemab, despite facing a scandal involving the SEC. Learn more about the latest updates on donanemab and the company's progress in the field of Alzheimer's research.
Read more
2024-10-05 (capitanbado.com)
New treatments against Alzheimer's: revolution or illusion?
Two new drugs that promise to slow Alzheimer's disease are generating controversy in the medical world. Some think they are a
Read more
2024-09-20 (t13.cl)
New treatments against Alzheimer's: revolution or illusion?
New drugs that promise to slow down Alzheimer's are generating controversy in medicine. Some think they are an unprecedented opportunity.
Read more
2024-09-03 (pharmavoice.com)
FDA adcomm reform talks heat up
As the agency considers eliminating adcomm votes from the approval process, members vie to have their voices heard.
Read more
2024-08-21 (statnews.com)
Alzheimer’s drug may raise the risk of brain bleed in patients with Down syndrome
The cerebral vasculature of people with Down syndrome could put them at a higher risk for hemorrhages, new study showed.
Read more
2024-08-09 (psychiatryadvisor.com)
The Aducanumab Controversy: Accelerated FDA Approval Leads to Agency Distrust
The aducanumab controversy involves the US FDA’s expedited approval of the AD drug, despite a lack of efficacy data and a problematic safety profile.
Read more
2024-07-26 (aol.com)
How a new FDA-approved drug can — and can’t — help people with Alzheimer’s
If you have a loved one with Alzheimer’s disease, you may have read about a newly approved drug. And you may have heard that the drug has caused some controversy. So, what’s really going on?
Read more
2024-07-19 (neurologyadvisor.com)
The Aducanumab Controversy: Accelerated FDA Approval Leads to Agency Distrust
The aducanumab controversy involves the US FDA’s expedited approval of the AD drug, despite a lack of efficacy data and a problematic safety profile.
Read more
2024-06-12 (proinvestor.com)
Anavex Dialogue with EMA on approval of 2-73 in Alzheimer's!! !
Anavex is in dialogue with the EMA about market approval of 2-73 in Alzheimer's! Anavex must have the complete data from the AD phase 2/3 trial when they choose to go to EMA now. EMA must also have seen complete e
Read more
2024-05-23 (pharmaphorum.com)
NICE and the controversy over a ‘clinically distinct disease’ designation
The debate rages on as NICE considers a 'clinically distinct disease' classification. Learn how this decision could reshape the STA process and patient treatment options.
Read more